Haslbeck M - Search Results

1

Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.

Pfützner A, Küstner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, Schatz H, Beyer J. Pfützner A, et al. Among authors: haslbeck m. Exp Clin Endocrinol Diabetes. 1996;104(1):25-30. doi: 10.1055/s-0029-1211418. Exp Clin Endocrinol Diabetes. 1996. PMID: 8750567 Clinical Trial.

2

Postprandial treatment with Lispro insulin.

Stiller R, Gudat U, Pfützner A, Trautmann ME, Haslbeck M. Stiller R, et al. Among authors: haslbeck m. Diabetes Metab. 1997 Jun;23(3):232-3. Diabetes Metab. 1997. PMID: 9234002 Clinical Trial. No abstract available.

3

[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].

Kellerer M, Jakob S, Linn T, Haslbeck M. Kellerer M, et al. Among authors: haslbeck m. MMW Fortschr Med. 2003 Dec 18;145(51-52):I-X; quiz XI-XII. MMW Fortschr Med. 2003. PMID: 14974337 Review. German. No abstract available.

4

Glycemic control in patients with type 2 diabetes mellitus with a disease-specific enteral formula: stage II of a randomized, controlled multicenter trial.

Pohl M, Mayr P, Mertl-Roetzer M, Lauster F, Haslbeck M, Hipper B, Steube D, Tietjen M, Eriksen J, Rahlfs VW. Pohl M, et al. Among authors: haslbeck m. JPEN J Parenter Enteral Nutr. 2009 Jan-Feb;33(1):37-49. doi: 10.1177/0148607108324582. Epub 2008 Nov 14. JPEN J Parenter Enteral Nutr. 2009. PMID: 19011146 Clinical Trial.

5

Glycaemic control in type II diabetic tube-fed patients with a new enteral formula low in carbohydrates and high in monounsaturated fatty acids: a randomised controlled trial.

Pohl M, Mayr P, Mertl-Roetzer M, Lauster F, Lerch M, Eriksen J, Haslbeck M, Rahlfs VW. Pohl M, et al. Among authors: haslbeck m. Eur J Clin Nutr. 2005 Nov;59(11):1221-32. doi: 10.1038/sj.ejcn.1602232. Eur J Clin Nutr. 2005. PMID: 16077745 Clinical Trial.

6

[17. Diabetes mellitus--classification, early detection and diagnosis].

Piwernetz K, Piehlmeier W, Landgraf R, Haslbeck M. Piwernetz K, et al. Among authors: haslbeck m. MMW Fortschr Med. 2001 Apr 5;143(14):I-X. MMW Fortschr Med. 2001. PMID: 11340916 German. No abstract available.

7

Clinical utility of nonenzymatically glycosylated blood proteins as an index of glucose control.

Schleicher ED, Gerbitz KD, Dolhofer R, Reindl E, Wieland OH, Edelmann E, Haslbeck M, Kemmler W, Walter H, Mehnert H. Schleicher ED, et al. Among authors: haslbeck m. Diabetes Care. 1984 Nov-Dec;7(6):548-56. doi: 10.2337/diacare.7.6.548. Diabetes Care. 1984. PMID: 6510180

8

The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT).

Haslbeck KM, Schleicher E, Bierhaus A, Nawroth P, Haslbeck M, Neundörfer B, Heuss D. Haslbeck KM, et al. Among authors: haslbeck m. Exp Clin Endocrinol Diabetes. 2005 May;113(5):288-91. doi: 10.1055/s-2005-865600. Exp Clin Endocrinol Diabetes. 2005. PMID: 15926115

9

Partial restoration of scintigraphically assessed cardiac sympathetic denervation in newly diagnosed patients with insulin-dependent (type 1) diabetes mellitus at one-year follow-up.

Schnell O, Muhr D, Dresel S, Weiss M, Haslbeck M, Standl E. Schnell O, et al. Among authors: haslbeck m. Diabet Med. 1997 Jan;14(1):57-62. doi: 10.1002/(SICI)1096-9136(199701)14:1<57::AID-DIA297>3.0.CO;2-7. Diabet Med. 1997. PMID: 9017355

10

[Oral diabetes therapy: when, what, how long?].

Haslbeck M. Haslbeck M. Med Welt. 1980 Jun 13;31(24):911-5. Med Welt. 1980. PMID: 7421516 German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters